Atara Biotherapeutics (ATRA) EPS (Weighted Average and Diluted) (2020 - 2026)
Atara Biotherapeutics (ATRA) reported EPS (Weighted Average and Diluted) of -$0.29 for Q1 2026, down 108.29% on a YoY basis from $3.5 in Q1 2025, and up 19.44% quarter-over-quarter from -$0.36 in Q4 2025.
Atara Biotherapeutics (ATRA) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
Atara Biotherapeutics has reported EPS (Weighted Average and Diluted) for 7 years, with the latest figure at -$0.29 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) fell 108.29% year-over-year to -$0.29; the trailing twelve-month figure through Mar 2026 stood at -$0.78 (up 70.0% YoY), and the FY2025 full-year result was $2.57, up 122.52% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.29, up from -$0.36 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $3.5 in Q1 2025, with the low at -$16.91 in Q2 2023.
- Historically, EPS (Weighted Average and Diluted) has averaged -$3.48 across 5 years, with a median of -$0.73 in 2022.
- Annual changes were most pronounced in 2023 — EPS (Weighted Average and Diluted) tumbled 9494.44% — and 2025, when it soared 161.95%.
- Atara Biotherapeutics' EPS (Weighted Average and Diluted) stood at -$0.73 in 2022, then tumbled by 1806.85% to -$13.92 in 2023, then jumped by 99.5% to -$0.07 in 2024, then plunged by 414.29% to -$0.36 in 2025, then climbed by 19.44% to -$0.29 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.29 (Q1 2026), -$0.36 (Q4 2025), and -$0.32 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 0.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -0.61 |
| 10 | Atara Biotherapeutics | 134.61 Mn | 126.21 Mn | 392,000.00 | -0.29 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.29 |
| Dec 31, 2025 | -0.36 |
| Sep 30, 2025 | -0.32 |
| Jun 30, 2025 | 0.19 |
| Mar 31, 2025 | 3.50 |
| Dec 31, 2024 | -0.07 |
| Sep 30, 2024 | -2.93 |
| Jun 30, 2024 | -3.10 |
| Mar 31, 2024 | -5.65 |
| Dec 31, 2023 | -13.92 |
| Sep 30, 2023 | -16.40 |
| Jun 30, 2023 | -16.91 |
| Mar 31, 2023 | -0.72 |
| Dec 31, 2022 | -0.73 |
| Sep 30, 2022 | -0.82 |
| Jun 30, 2022 | 0.18 |
| Mar 31, 2022 | -0.87 |
| Dec 31, 2021 | -0.96 |
| Sep 30, 2021 | -0.90 |
| Jun 30, 2021 | -0.91 |